{"name": "Tolera Therapeutics",
 "permalink": "tolera-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/tolera-therapeutics",
 "homepage_url": "http://www.tolera.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@tolera.com",
 "phone_number": "(269) 585-2100",
 "description": "",
 "created_at": "Wed May 27 09:46:06 UTC 2009",
 "updated_at": "Wed Oct 17 12:39:11 UTC 2012",
 "overview": "\u003Cp\u003ETolera Therapeutics Inc., founded under the scientific and medical direction of Maria Siemionow, M.D., Ph.D., D.Sc., is a spin-off of the Cleveland Clinic focused on bringing more specific, and safer therapies to market with competitive speed.\u003C/p\u003E\n\n\u003Cp\u003EThe company\u00e2\u20ac\u2122s technology stems from immune modulation and transplant research done at the Cleveland Clinic under the leadership of Dr. Siemionow, an internationally recognized leader in the fields of microsurgery and transplantation. In addition to her surgical skills, she has focused her research efforts on the development of therapies to promote life-long acceptance of organ and tissue transplants, while reducing or eliminating the need for chronic immunosuppression therapies and their dangerous side effects. In addition, Dr. Siemionow\u00e2\u20ac\u2122s efforts have led to new discoveries in immune system modulation. She has authored and contributed to over 180 peer reviewed articles on transplantation, immune suppression and organ tolerance.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[138,
       79],
      "assets/images/resized/0004/5655/45655v1-max-150x150.jpg"],
     [[138,
       79],
      "assets/images/resized/0004/5655/45655v1-max-250x250.jpg"],
     [[138,
       79],
      "assets/images/resized/0004/5655/45655v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "John",
      "last_name": "J. Puisis",
      "permalink": "john-j-puisis",
      "image":
       {"available_sizes":
         [[[110,
            110],
           "assets/images/resized/0004/5656/45656v1-max-150x150.jpg"],
          [[110,
            110],
           "assets/images/resized/0004/5656/45656v1-max-250x250.jpg"],
          [[110,
            110],
           "assets/images/resized/0004/5656/45656v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Chief Medical Officer",
    "person":
     {"first_name": "Maria",
      "last_name": "Siemionow",
      "permalink": "maria-siemionow",
      "image":
       {"available_sizes":
         [[[110,
            110],
           "assets/images/resized/0004/5657/45657v1-max-150x150.jpg"],
          [[110,
            110],
           "assets/images/resized/0004/5657/45657v1-max-250x250.jpg"],
          [[110,
            110],
           "assets/images/resized/0004/5657/45657v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Chief Operating Officer",
    "person":
     {"first_name": "James",
      "last_name": "J. Herrmann",
      "permalink": "james-j-herrmann",
      "image":
       {"available_sizes":
         [[[110,
            110],
           "assets/images/resized/0004/5658/45658v1-max-150x150.jpg"],
          [[110,
            110],
           "assets/images/resized/0004/5658/45658v1-max-250x250.jpg"],
          [[110,
            110],
           "assets/images/resized/0004/5658/45658v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$5.5M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "",
    "source_description": "Capital Funding Report",
    "raised_amount": null,
    "raised_currency_code": null,
    "funded_year": 2008,
    "funded_month": 6,
    "funded_day": 16,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Southwest Michigan First, Investment Arm",
         "permalink": "southwest-michigan-first-investment-arm",
         "image":
          {"available_sizes":
            [[[150,
               29],
              "assets/images/resized/0004/5659/45659v2-max-150x150.png"],
             [[250,
               49],
              "assets/images/resized/0004/5659/45659v2-max-250x250.png"],
             [[450,
               88],
              "assets/images/resized/0004/5659/45659v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Triathlon Medical Venture Partners",
         "permalink": "triathlon-medical-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               49],
              "assets/images/resized/0004/5663/45663v2-max-150x150.png"],
             [[200,
               66],
              "assets/images/resized/0004/5663/45663v2-max-250x250.png"],
             [[200,
               66],
              "assets/images/resized/0004/5663/45663v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Hopen Therapeutics",
         "permalink": "hopen-therapeutics",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0004/5668/45668v1-max-150x150.png"],
             [[177,
               59],
              "assets/images/resized/0004/5668/45668v1-max-250x250.png"],
             [[177,
               59],
              "assets/images/resized/0004/5668/45668v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://www.prnewswire.com/news-releases/tolera-therapeutics-closes-series-b-3-financing-raises-55-million-to-submit-phase-3-special-protocol-assessment-for-its-immune-targeting-biologic-drug-in-kidney-transplantation-174443781.html",
    "source_description": "Tolera Therapeutics closes Series B-3 financing, raises $5.5 million to submit Phase 3 Special Protocol Assessment for its immune targeting biologic drug in kidney transplantation PR Newswire",
    "raised_amount": 5500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 10,
    "funded_day": 16,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Hopen Life Science Ventures",
         "permalink": "hopen-life-science-ventures",
         "image":
          {"available_sizes":
            [[[150,
               63],
              "assets/images/resized/0021/5931/215931v1-max-150x150.jpg"],
             [[244,
               104],
              "assets/images/resized/0021/5931/215931v1-max-250x250.jpg"],
             [[244,
               104],
              "assets/images/resized/0021/5931/215931v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Triathlon Medical Venture Partners",
         "permalink": "triathlon-medical-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               49],
              "assets/images/resized/0004/5663/45663v2-max-150x150.png"],
             [[200,
               66],
              "assets/images/resized/0004/5663/45663v2-max-250x250.png"],
             [[200,
               66],
              "assets/images/resized/0004/5663/45663v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "SWMF Life Science Fund",
         "permalink": "swmf-life-science-fund",
         "image":
          {"available_sizes":
            [[[150,
               29],
              "assets/images/resized/0026/1347/261347v1-max-150x150.png"],
             [[250,
               49],
              "assets/images/resized/0026/1347/261347v1-max-250x250.png"],
             [[450,
               88],
              "assets/images/resized/0026/1347/261347v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "350 E. Michigan Avenue",
    "address2": "Suite 205",
    "zip_code": "49007",
    "city": "Kalamazoo",
    "state_code": "MI",
    "country_code": "USA",
    "latitude": 42.2927344,
    "longitude": -85.5796432}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        81],
       "assets/images/resized/0004/5653/45653v1-max-150x150.jpg"],
      [[250,
        135],
       "assets/images/resized/0004/5653/45653v1-max-250x250.jpg"],
      [[450,
        243],
       "assets/images/resized/0004/5653/45653v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}